772-773 / 1983
Summary
•
3 HGG; 2 LGG; 3 Mets
•
No meningioma, pituitary, medulloblastoma, pilocytic astrocytoma
•
Focus on treatment and prognosis
•
For glioma, grade still matters
•
But molecular pathology is becoming more important for risk stratification
•
We are not going to reduce the dose in IDH-mut GBM
•
Brain mets – still poor evidence base
•
Clinically fascinating area
•
Good mix of technology and humanity